Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Biosimilar Interleukins Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The biosimilar interleukins market has experienced substantial expansion in recent years. Its value is expected to increase from $7.52 billion in 2025 to $10.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 40.2%. Historically, this growth can be linked to the expensive nature of originator interleukin biologics, the rising occurrence of autoimmune and inflammatory diseases, the increasing impact of rheumatoid arthritis and psoriasis, limited patient availability of biologic treatments, and a growing understanding of biologics’ role in immune modulation.
The biosimilar interleukins market size is projected for significant expansion in the coming years. This market is anticipated to reach a valuation of $41.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 40.6%. Several factors are contributing to this projected growth during the forecast period, including the expiration of patents for branded interleukins, the expanding pipelines of biosimilar clinical trials, greater acceptance of biosimilars by physicians, government policies that support biosimilar adoption, and a growing need for cost-effective biologic treatments for cancer and immunological conditions. Key trends expected in the forecast period involve a surge in the use of biosimilar interleukins for treating autoimmune diseases, an escalating demand for economical substitutes to original biologic drugs, an increase in biosimilar approvals for various indications, the expanded application of interleukins in managing chronic inflammatory conditions, and the reinforcement of regulatory structures that facilitate biosimilar uptake.
Get A Free Sample Report With In-Depth Market Insights:
Biosimilar Interleukins Market Growth Catalysts And Demand Drivers
The anticipated rise in autoimmune conditions, such as psoriasis and rheumatoid arthritis, is projected to accelerate the expansion of the interleukin biosimilars market over the forecast period. Autoimmune disorders are characterized by immune cells’ inability to differentiate healthy cells from potentially harmful antibodies. Biologic drugs, like anti-interleukin antibodies, have exhibited significant clinical benefits in regulating cellular processes, including proliferation, activation, and migration. For instance, in February 2024, reports from the National Institutes of Health (NIH), a US-based biomedical research agency, estimated annual global increases in the incidence and prevalence of autoimmune diseases at 19.1% and 12.5%, respectively. Therefore, the increasing occurrence of autoimmune diseases is boosting demand within the biosimilar interleukins market and is expected to drive the growth of the market.
Biosimilar Interleukins Market Segment Analysis Spotlighting Growth Areas
The biosimilar interleukins market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
Biosimilar Interleukins Market Trends Shaping Long-Term Demand
Key companies operating in the biosimilar interleukins market are introducing new products such as Tofidence (tocilizumab-bavi) to enhance their market profitability. Tofidence is a monoclonal antibody that targets and connects to interleukin-6 receptors, used in treating various inflammatory autoimmune disorders. For instance, in September 2023, Biogen Inc., a US-based biotechnology firm, obtained FDA approval for Tofidence (tocilizumab-bavi) as the first biosimilar referencing Genentech’s Actemra (tocilizumab). Tofidence is administered through intravenous infusion and has been approved for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Biosimilar Interleukins Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
View The Full Biosimilar Interleukins Market Report:
Biosimilar Interleukins Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in the biosimilar interleukins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
